<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(7)</volume><submitter>Li J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Small cell cancer (SmCC) of the esophagus is a rare malignancy with an aggressive behavior associated with poor survival. The present study aims to determine the clinicopathological characteristics, therapeutic and prognosis.&lt;h4>Methods&lt;/h4>Patients with SmCC of the esophagus, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological characteristics were described and the prognostic factors were further determined using Cox regression analysis.&lt;h4>Results&lt;/h4>The median overall survival (mOS) of all 515 patients with SmCC of the esophagus was 7.0 months, and the 1-, 2-, and 5-year survival rates were 31.5%, 14.7%, 6.00%, respectively. Patients with chemoradiotherapy (mOS: 12.0 months) had be</pubmed_abstract><journal>Journal of thoracic disease</journal><pagination>3529-3538</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7399392</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Population-based analysis of small cell carcinoma of the esophagus using the SEER database.</pubmed_title><pmcid>PMC7399392</pmcid><pubmed_authors>Zhou L</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Niu J</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Wang H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Population-based analysis of small cell carcinoma of the esophagus using the SEER database.</name><description>&lt;h4>Background&lt;/h4>Small cell cancer (SmCC) of the esophagus is a rare malignancy with an aggressive behavior associated with poor survival. The present study aims to determine the clinicopathological characteristics, therapeutic and prognosis.&lt;h4>Methods&lt;/h4>Patients with SmCC of the esophagus, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological characteristics were described and the prognostic factors were further determined using Cox regression analysis.&lt;h4>Results&lt;/h4>The median overall survival (mOS) of all 515 patients with SmCC of the esophagus was 7.0 months, and the 1-, 2-, and 5-year survival rates were 31.5%, 14.7%, 6.00%, respectively. Patients with chemoradiotherapy (mOS: 12.0 months) had be</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-25T17:42:33.689Z</modification><creation>2025-04-06T06:00:30.386Z</creation></dates><accession>S-EPMC7399392</accession><cross_references><pubmed>32802432</pubmed><doi>10.21037/jtd-20-1428</doi></cross_references></HashMap>